Category - Feature

Feature

Inagene personalizing pain management with comprehensive genetic test

Closely-held pharmacogenetics company, Inagene Diagnostics, aims to replace the “trial-and-error” approach to pain management with a comprehensive genetic test that helps physicians provide personalized pain management...

January 28, 2020

Feature

Liminal BioSciences making headway in strategic transformation

Liminal BioSciences (NASDAQ, TSX:LMNL) is undergoing a significant strategic transformation to simplify its operations, achieve financial stability and focus R&D on small molecule therapeutics. “This is a refresh of...

January 21, 2020

Feature

BriaCell breast cancer program ready for partnering

BriaCell Therapeutics (OTCQB:BCTXD; TSXV:BCT) believes its Phase 2 clinical program in advanced breast cancer, which includes an ongoing combination study of its Bria-IMT with immune checkpoint inhibitors such as...

January 7, 2020

Feature

Clene Nanomedicine developing first nanotherapeutic for neurodegenerative disease

Closely-held Clene Nanomedicine is developing catalytic drugs to treat neurodegenerative diseases, using its clean surface nanocrystal (CSN) therapeutics platform to increase cellular bioenergy. “We’re the first...

December 17, 2019

Feature

Kane Biotech completes 12-month transformation; ready for robust growth

Kane Biotech (TSXV:KNE) has completed a major transformation during the past year, relaunching its animal health business, expanding into human health, raising non-dilutive financing, and hiring a new executive team...

December 10, 2019

Feature

Squarex hopes to begin pivotal testing to prevent recurring cold sores in 2020

Closely-held Squarex will be seeking an end-of-Phase 2 meeting with the FDA in the first quarter of 2020 as a steppingstone for pivotal testing of its SQX770 topical treatment for the prevention of recurrent cold sores...

December 3, 2019

Feature

Artelo readies Phase 1b/2a trial of cannabinoid agonist for cancer-related anorexia

Artelo Biosciences (NASDAQ:ARTL) is gearing up to begin a UK-based Phase 1b/2a study of its cannabinoid agonist drug candidate, ART 27.13, which has the potential to stimulate cancer patients’ appetite and promote...

November 26, 2019

Feature

Ventripoint readies sales push of 3D heart imaging VMS+ 3.0 device

With FDA approval in October of its VMS+ 3.0 system, which turns 2D echocardiograms into MRI equivalent 3D images, Ventripoint Diagnostics (TSXV:VPT, OTCQB:VPTDF) is gearing up for a major sales and marketing program in...

November 19, 2019

Feature

Spring Bank heading into data-rich 2020

Spring Bank Pharmaceuticals (NASDAQ:SBPH) will be reporting clinical data readouts throughout 2020 as it advances a portfolio of three drug candidates for the treatment of chronic hepatitis B virus (HBV) as well as...

November 12, 2019

Feature

Lobo Genetics enabling personalized cannabis product selection based on consumers’ genes

Closely-held Lobo Genetics is taking its cannabis genetic profile testing to the next level. “We started with genetic tests and genetic profiling and now we are complementing that by helping guide consumers to the right...

November 5, 2019

Category - Feature

Inagene personalizing pain management with comprehensive genetic test

Liminal BioSciences making headway in strategic transformation

BriaCell breast cancer program ready for partnering

Clene Nanomedicine developing first nanotherapeutic for neurodegenerative disease

Kane Biotech completes 12-month transformation; ready for robust growth

Squarex hopes to begin pivotal testing to prevent recurring cold sores in 2020

Artelo readies Phase 1b/2a trial of cannabinoid agonist for cancer-related anorexia

Ventripoint readies sales push of 3D heart imaging VMS+ 3.0 device

Spring Bank heading into data-rich 2020

Lobo Genetics enabling personalized cannabis product selection based on consumers’ genes

General

More